Israeli biotech receives $30M: Lutris Pharma reported the funding might help it exam a topical gel that aims to lessen EGFRi-induced rashes because of certain most cancers medicine. We've been excited about the opportunity to collaborate with BioAge to share Lilly’s experience in incret